4 Healthcare Stock Stories for Prudent Investors

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

The Medicines Company (NASDAQ:MDCO): Closing price $28.83

The firm reported results on Tuesday for its pivotal Phase 3 clinical trial of cangrelor, in development to prevent platelet activation and aggregation which leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention. Subsequent to the recommendation of the trial’s Data Safety Monitoring Board in July, to continue the protocol as planned, the CHAMPIONPHOENIX trial finalized enrollment in October. Folloiwng a successful data lock, the data analysis indicated that the protocol defined primary composite efficacy endpoint of death, myocardial infarction, ischemia driven revascularization, and stent thrombosis at 48 hours was met. Cangrelor showed statistically significant improvement when compared to clopidogrel.

mdco

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business